A non-interventional, post-authorisation safety study of patients treated with efgartigimod alfa

First published: 13/03/2024

Last updated: 13/03/2024





Administrative details

EU PAS number
EUPAS100000019
Study ID
100000019
DARWIN EU® study
No
Study countries
European Union
United States

Study description

This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.

Enrolment of patients will be over at least a 5-year period. The follow up of patients will continue for 5 years from the time the last patient has been enrolled. Patients will be followed up regardless of whether they continue or discontinue efgartigimod.

Study status

Ongoing

Research institutions and networks

Institutions

United BioSource Corporation (UBC)
Switzerland
First published: 25/04/2013
Last updated: 06/03/2024
Institution Non-Pharmaceutical company ENCePP partner

Contact details

Study institution contact

Sabine Coppieters Clinicaltrials@argenx.com

Study contact

Clinicaltrials@argenx.com

Primary lead investigator

Not yet assigned

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 31/03/2024

Study start date

Actual: 14/12/2023

Date of final study report

Planned: 01/06/2034

Study protocol

ARGX-113-PASS-2208-Protocol_Redacted.pdf(451.46 KB)

Regulatory

Was the study required by a regulatory body? Yes
Is the study required by a Risk Management Plan (RMP)? EU RMP category 3 (required)
Methodological aspects
Study type
Study type list
Study topic: Human medicinal product
Study type: Non-interventional study
Scope of the study: Other
If 'other', further details on the scope of the study Post-Authorization Safety Study (PASS)
Data collection methods: Combined primary data collection and secondary use of data
Study design:

This is a non-interventional, prospective, post authorisation safety study.

Main study objective:

A non-interventional 10-year Post-Authorization Safety Study (PASS) in a post-marketing setting comparing cohorts of patients with gMG treated with efgartigimod to those treated with other MG medication, in order to estimate the incidence rates of serious infection and other safety events.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Name of medicine

VYVGART

Study drug International non-proprietary name (INN) or common name EFGARTIGIMOD ALFA

Medical condition to be studied

Myasthenia gravis

Population studied

Age groups

Adult and elderly population (≥18 years)

Adults (18 to < 65 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

680

Study design details

Setting

Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enrol into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enrol into the non-efgartigimod cohort.

Outcomes

To evaluate the overall long-term safety of efgartigimod including the occurrence of serious infections in gMG patients treated with efgartigimod compared to gMG patients not exposed to efgartigimod.

Data management

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No